Prognostic and clinicopathological value of p53 expression in renal cell carcinoma: A meta-analysis

23Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.

Abstract

Background: The prognostic value of p53 expression in renal cell carcinoma (RCC) had been investigated in previous studies; however, the results remain inconsistent. This study was performed to investigate the prognostic and clinicopathological significance of p53 protein expression in RCC. Materials and Methods: Literature was identified from PubMed, Embase, Web of Science, and Cochrane database, which investigated the relationships between p53 expression and outcomes. Hazard ratios (HRs) for survival outcomes and odds ratios (ORs) for clinical parameters associated with p53 were extracted from eligible studies. Heterogeneity was assessed using the I2 value. The fixed-effects model was used if there was no evidence of heterogeneity; otherwise, the random-effects model was used. Publication bias was evaluated using Begg's funnel plots and Egger's regression test. Results: A total of 2,013 patients from 22 studies were included in the metaanalysis. The results showed that p53 positive expression is associated with poor overall survival (OS) (HR = 2.17, 95% confidence [CI]: 1.51-3.13) and cancer-specific survival (CSS) (HR = 1.59, 95% CI: 1.19-2.12) in RCC. In addition, p53 positive expression was closely correlated with TNM stage (III/IV vs. I/II: OR = 2.51, 95% CI: 1.05-6.00), Fuhrman grade (III/IV vs. I/II: OR = 1.80, 95% CI: 1.24-2.63), and distant metastasis (M1 vs. M0: OR = 1.70, 95% CI: 1.16-2.49), but not related to lymph node involvement (N1 vs. N0: OR = 1.32, 95% CI: 0.80-2.18), primary tumor stage (pT3/pT4 vs. pT1/pT2: OR = 1.16, 95% CI: 0.88-1.53), and sex (n = 2, male vs. female, OR = 1.09, 95% CI: 0.70-1.68). Conclusions: This study suggests that p53 positive expression is correlated with poor prognosis and advanced clinicopathological features in patients with RCC, which indicates that p53 is a potentially effective therapeutic target.

References Powered by Scopus

Measuring inconsistency in meta-analyses

48825Citations
N/AReaders
Get full text

Global cancer statistics, 2012

25686Citations
N/AReaders
Get full text

Cancer statistics, 2016

23617Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma

71Citations
N/AReaders
Get full text

DNA damaging agents and DNA repair: From carcinogenesis to cancer therapy

45Citations
N/AReaders
Get full text

Histone deacetylase inhibitors dysregulate DNA repair proteins and antagonize metastasis-associated processes

38Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Wang, Z., Peng, S., Jiang, N., Wang, A., Liu, S., Xie, H., … Niu, Y. (2017). Prognostic and clinicopathological value of p53 expression in renal cell carcinoma: A meta-analysis. Oncotarget, 8(60), 102361–102370. https://doi.org/10.18632/oncotarget.21971

Readers over time

‘17‘18‘19‘20‘21‘22‘23‘2402468

Readers' Seniority

Tooltip

Lecturer / Post doc 3

38%

PhD / Post grad / Masters / Doc 3

38%

Professor / Associate Prof. 1

13%

Researcher 1

13%

Readers' Discipline

Tooltip

Medicine and Dentistry 5

56%

Biochemistry, Genetics and Molecular Bi... 2

22%

Agricultural and Biological Sciences 1

11%

Environmental Science 1

11%

Save time finding and organizing research with Mendeley

Sign up for free
0